Back to Results

MannKind Corp (MNKD)

Featured in Rapid Revenue Growth High-Beta Stocks Small-Cap Stocks

MannKind Corp. is a biotechnology company focused on therapies for chronic and serious diseases. Its commercial portfolio includes Afrezza, an inhaled insulin for adults with diabetes; Furoscix, a furosemide injection used to treat edema in certain pediatric patients with chronic heart failure or chronic kidney disease; V-Go, a wearable insulin delivery device; and Tyvaso DPI for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company is also developing product candidates for orphan lung diseases, including MNKD-201 for idiopathic pulmonary fibrosis and MNKD-701. MannKind has collaboration and license arrangements with United Therapeutics for Tyvaso DPI and with Thirona related to pulmonary fibrosis research. Founded in 1991, the company is headquartered in Danbury, Connecticut.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-MNKD
$4.37
8.9% Upside
Fair
$7.59
89.1% Upside
Bargain
Good
—
—
—
0.0%
August 12, 2026
-51.9x
-21.0x
3.4x
1.23 B
1.541 B
26.1%
98.1%
-10.1
—
-55.0%
Send a message
Valuation • Fair Value

MannKind Corp (NASDAQ-MNKD) Fair Value by Valuation Model

Compare the primary fair value estimate for MannKind Corp (NASDAQ-MNKD) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$4.37

Estimated upside of 8.9% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$5.31

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$3.59

Comparable-company valuation reference.

Analyst Price Target

$7.59

Analysts imply upside of 89.1%.

How to read these valuation models

Use this section to compare the primary fair value estimate for MannKind Corp (NASDAQ-MNKD) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for MannKind Corp (NASDAQ-MNKD)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

360.8 M

Current operating scale indicator.

Revenue Forecast

456.6 M

Forward revenue estimate.

EBITDA

35.323 M

Current operating profitability reference.

EBITDA Forecast

100.4 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review MannKind Corp (NASDAQ-MNKD) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for MannKind Corp (NASDAQ-MNKD)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Good

Positive financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

-0.34

Higher caution zone on this screen.

Altman Z-Score

-10.1

Lower score that deserves closer risk review.

FCF / Net Income

-55.0%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for MannKind Corp (NASDAQ-MNKD). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for MannKind Corp (NASDAQ-MNKD)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 12, 2026

Days to Earnings

22

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for MannKind Corp (NASDAQ-MNKD), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

MannKind Corp (NASDAQ-MNKD) Stock Forecast & Technical Outlook

Review MannKind Corp (NASDAQ-MNKD) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Sell

The 15-minute technical read for MannKind Corp (NASDAQ-MNKD) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for MannKind Corp (NASDAQ-MNKD) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for MannKind Corp (NASDAQ-MNKD) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Neutral

The weekly technical read for MannKind Corp (NASDAQ-MNKD) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for MannKind Corp (NASDAQ-MNKD) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for MannKind Corp (NASDAQ-MNKD)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, MannKind Corp (NASDAQ-MNKD) has a Strong Buy consensus, with 7 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 7
Hold 1
Sell 0
FAQ • Fast Investor Answers

MannKind Corp (NASDAQ-MNKD) Stock FAQ

Quick answers about MannKind Corp (NASDAQ-MNKD) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$4.37
Estimated upside 8.9%
Valuation Rating
Undervalued
Estimated upside of 8.9%
Analyst Target
$7.59
Implied upside 89.1%
Financial Health
Good
Current financial-health read

The current fair value estimate for MannKind Corp (NASDAQ-MNKD) is $4.37. This implies an estimated upside of 8.9% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 8.9% versus the current market price.

The available analyst price target for MannKind Corp (NASDAQ-MNKD) is $7.59. The analyst target implies estimated upside of 89.1%.

The current financial health read for MannKind Corp (NASDAQ-MNKD) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for MannKind Corp (NASDAQ-MNKD) is August 12, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for MannKind Corp (NASDAQ-MNKD) is -51.9x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for MannKind Corp is 1.23 B.

The current enterprise value listed for MannKind Corp is 1.541 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for MannKind Corp is NASDAQ-MNKD, and the stock is listed on NASDAQ.

MannKind Corp (NASDAQ-MNKD) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for MannKind Corp is 26.1%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for MannKind Corp is 98.1%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on NASDAQ View more

Amgen Inc (AMGN) Amgen Inc (AMGN)
Gilead Sciences Inc (GILD) Gilead Sciences Inc (GILD)
Vertex Pharmaceuticals Inc (VRTX) Vertex Pharmaceuticals Inc (VRTX)
Regeneron Pharmaceuticals Inc (REGN) Regeneron Pharmaceuticals Inc (REGN)
Argenx NV ADR (ARGX) Argenx NV ADR (ARGX)
Revolution Medicines Inc (RVMD) Revolution Medicines Inc (RVMD)
Natera Inc (NTRA) Natera Inc (NTRA)
Alnylam Pharmaceuticals Inc (ALNY) Alnylam Pharmaceuticals Inc (ALNY)
BeOne Medicines AG DRC (ONC) BeOne Medicines AG DRC (ONC)
Biogen Inc (BIIB) Biogen Inc (BIIB)
Roivant Sciences Ltd (ROIV) Roivant Sciences Ltd (ROIV)
Moderna Inc (MRNA) Moderna Inc (MRNA)
BioNTech SE (BNTX) BioNTech SE (BNTX)
Insmed Inc (INSM) Insmed Inc (INSM)
Incyte Corporation (INCY) Incyte Corporation (INCY)
United Therapeutics Corporation (UTHR) United Therapeutics Corporation (UTHR)
Neurocrine Biosciences Inc (NBIX) Neurocrine Biosciences Inc (NBIX)
Genmab AS (GMAB) Genmab AS (GMAB)
BridgeBio Pharma Inc (BBIO) BridgeBio Pharma Inc (BBIO)
Ascendis Pharma AS (ASND) Ascendis Pharma AS (ASND)
Exelixis Inc (EXEL) Exelixis Inc (EXEL)
Madrigal Pharmaceuticals Inc (MDGL) Madrigal Pharmaceuticals Inc (MDGL)
Abivax SA ADR (ABVX) Abivax SA ADR (ABVX)
Biomarin Pharmaceutical Inc (BMRN) Biomarin Pharmaceutical Inc (BMRN)